Friday 6 November 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue: +10.5%
EPS: +6.00%
Free cash flow: −1.84%
Total debt: +0.10%

Quarter to September 2026, against a year earlier

101.94 1.12 +1.11%

Follow EW

Alert me

Market cap: $58.1B
P/E: 56.7×
Fwd P/E: 36.5×
Dividend yield: —
F-score: 5/9
Altman Z: 11.54
Beneish M: −2.48
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Edwards Lifesciences Corporation (EW) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Edwards Lifesciences Corporation (EW) trades at a price to free cash flow of 41.5×. Over the past ten years it has ranged from 14.3× (January 2015) to 226× (April 2024); the current reading is higher than 25% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/EW/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Edwards Lifesciences Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/EW/metrics/price-to-free-cash-flow">Edwards Lifesciences Corporation (EW) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	38.2×	(77.56%)
FY2024	170×	133.75%
FY2023	72.8×	50.36%
FY2022	48.4×	(15.90%)
FY2021	57.6×	(35.12%)
FY2020	88.8×	65.28%
FY2019	53.7×	14.82%
FY2018	46.8×	62.79%
FY2017	28.7×	(31.75%)
FY2016	42.1×	6.69%

Period	Price to free cash flow	Change
Sep 2026	35.7×	(3.94%)
Jun 2026	37.1×	(15.14%)
Mar 2026	43.8×	14.59%
Dec 2025	38.2×	(34.96%)
43 more quarters	Free account

Against its own ten years

Low 14.3× High 226×

Ten-year median 51.5×

Current reading's percentile 25

Company	Price to free cash flow
PHG Koninklijke Philips N.V. compare	14.1×
ZBH Zimmer Biomet Holdings, Inc. compare	18.2×
BSX Boston Scientific Corporation compare	19.3×
GEHC GE HealthCare Technologies Inc. compare	19.9×
MDT Medtronic PLC compare	21.8×
STE STERIS plc compare	26.4×
DXCM DexCom, Inc. compare	28.8×
SYK Stryker Corporation compare	28.9×
EW Edwards Lifesciences Corporation	41.5×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Edwards Lifesciences Corporation (EW) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on EW

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on EW

Stockrow Weekly